UCSF Medical Center Moffitt-Long Hospital
Welcome,         Profile    Billing    Logout  
 7 Trials 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Kathleen D
I-SPY_COVID, NCT04488081: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Recruiting
2
1500
US
Remdesivir, GS-5734, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Firazyr, Apremilast, Otezla, dornase alfa, Pulmozyme, Celecoxib, celebrex, Famotidine, Pepcid, IC14, Aviptadil, Zyesami, narsoplimab, OMS721, Cyproheptadine, periactin, Cyclosporine, CsA
QuantumLeap Healthcare Collaborative, University of California, San Francisco, University of Pennsylvania, Emory University, University of Alabama at Birmingham, University of Colorado, Denver, University of Southern California, Yale University, Wake Forest University Health Sciences, Sanford Health, Long Beach Memorial Medical Center, Georgetown University, University of California, Davis, Hoag Memorial Hospital Presbyterian, Main Line Health, DHR Health Institute for Research and Development, University of California, Irvine, Corewell Health, Kaiser Permanente, University of Michigan, West Virginia University, University of Miami, University Hospitals Cleveland Medical Center, Virtua Health, M.D. Anderson Cancer Center
COVID-19
07/28
07/30
NCT06654193: Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

Not yet recruiting
1/2
70
US
Allogeneic HB-adMSCs, Normal Saline
Hope Biosciences, The University of Texas Health Science Center, Houston, University of California, San Francisco, University of Alabama at Birmingham
Acute Kidney Injury
01/28
01/28
LIBERATE-D, NCT04218370: Liberation From Acute Dialysis

Recruiting
N/A
220
US
Dialysis
University of California, San Francisco, Vanderbilt University Medical Center, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Kidney Injury, Kidney; Disease, Acute, Dialysis Related Complication
03/25
06/25
Lee, Benjamin
PROBE, NCT04510597: Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the Trial

Recruiting
3
364
US
Cytoreductive Nephrectomy, Active Comparator
SWOG Cancer Research Network, National Cancer Institute (NCI)
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/33
07/33
NCT03701581: 4-aminopyridine Treatment for Nerve Injury

Active, not recruiting
2/3
70
US
4-Aminopyridine, 4-AP, Fampridine, Dalfampridine, Placebo
John Elfar, University of Arizona
Nerve Injury, Prostate Cancer
07/25
12/25
NCT06526858: Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension

Not yet recruiting
N/A
15
US
HyperQureTM Renal Denervation (RDN) System:, Extravascular renal denervation, Laparoscopic renal denervation
DeepQure Inc.
Resistant Hypertension
08/25
05/28
Hsu, Chi-yuan
LIBERATE-D, NCT04218370: Liberation From Acute Dialysis

Recruiting
N/A
220
US
Dialysis
University of California, San Francisco, Vanderbilt University Medical Center, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Kidney Injury, Kidney; Disease, Acute, Dialysis Related Complication
03/25
06/25
APOLLO, NCT03615235: APOL1 Long-term Kidney Transplantation Outcomes Network

Recruiting
N/A
5000
US
Wake Forest University Health Sciences, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
12/25
12/25
Home-BP, NCT05159999: The Home Blood Pressure (BP) Trial

Recruiting
N/A
200
US
Dry weight target adjustment, Anti-hypertensive medications
University of Washington, University of California, San Francisco, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Renal Disease on Dialysis
04/26
04/26

Download Options